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http://www.biomedcentral.com/1741-7015/12/154RESEARCH ARTICLE Open AccessNon-invasive score identifies ultrasonography-
diagnosed non-alcoholic fatty liver disease and
predicts mortality in the USA
Ching-Lung Cheung1,2,3,4,5*, Karen SL Lam1,2,5, Ian CK Wong3,5 and Bernard MY Cheung1,2,5*Abstract
Background: Several non-invasive prediction scores for non-alcoholic fatty liver disease (NAFLD) have been
developed, but their performance has not been compared and validated in the same population, and whether these
prediction scores can predict clinical outcomes remains unknown. In this study, we aimed to validate and compare
the performance of four NAFLD prediction scores: fatty liver index, hepatic steatosis index, lipid accumulation product,
and NAFLD liver fat score (LFS), and to evaluate the ability of the best NAFLD prediction score to predict mortality.
Methods: We analyzed data from the National Health and Nutrition Examination Survey conducted in 1988 to 1994,
and subsequent follow-up data for mortality up to December 31, 2006. NAFLD was defined by ultrasonographic
detection of hepatic steatosis in the absence of other known liver diseases.
Results: In a group of 5,184 participants, LFS consistently showed the highest area under the curve for predicting the
presence of NAFLD. During a median follow-up of 14.7 years (range 0.1 to 18.2 years) and 83,830.5 person-years,
participants in the high LFS group (LFS ≥1.257) had a higher cardiovascular and liver-related mortality than participants in
the low (LFS≤−1.413; cardiovascular hazard ratio (HR) = 2.24, 95% CI 1.03 to 4.88; liver HR = 31.25, 95% CI 3.13 to 333.33)
or intermediate (−1.413 < LFS < 1.257; cardiovascular HR = 2.3, 95% CI 1.19 to 4.48; liver HR = 30.3, 95% CI 4 to 250) LFS
groups in the fully adjusted model. Similar results were obtained when LFS was treated as a continuous variable.
Conclusions: LFS is the best non-invasive prediction score for NAFLD, and people with a high LFS score have an
increased risk for cardiovascular and liver-related mortality.
Keywords: NAFLD, NAFLD liver fat score, MortalityBackground
Non-alcoholic fatty liver disease (NAFLD) represents a
spectrum of progressive liver disease ranging from sim-
ple steatosis to non-alcoholic steatohepatitis (NASH), fi-
brosis, and cirrhosis, in the absence of excessive alcohol
consumption. NAFLD is regarded as a hepatic manifest-
ation of metabolic syndrome (MetS) [1], therefore the
presence of NAFLD is not only strongly associated with
liver-related mortality, but also with diseases related to
the MetS, such as diabetes and cardiovascular diseases
[2,3]. As NAFLD is highly prevalent and affects up to* Correspondence: lung1212@hku.hk; mycheung@hku.hk
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unless otherwise stated.30% of the general adult population [4], screening for
and diagnosing NAFLD has become an important issue
in public health to prevent NAFLD-related complica-
tions and reduce healthcare costs.
Liver biopsy remains the “gold standard” for NAFLD
diagnosis; however, this is an invasive technique ma-
king it impractical to be used widely. Ultrasonography is
therefore the recommended first-line imaging technique
in clinical practice, although it is known to have limited
sensitivity [3]. Other non-invasive tools have been de-
veloped for diagnosing NAFLD, such as computed tom-
ography and proton magnetic resonance spectroscopy
(1H-MRS). However, these tools are expensive and time-
consuming, and are not considered cost-effective for
large-scale NAFLD screening. Recently, five biomarker-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been developed: SteatoTest [5], fatty liver index (FLI)
[6], NAFLD liver fat score (LFS) [7], lipid accumulation
product (LAP) [8], and hepatic steatosis index (HSI) [9].
These scores are derived from simple clinical risk fac-
tors and biomarkers, and can therefore potentially be
used for large-scale NAFLD screening. However, dif-
ferent definitions and techniques were used to define
NAFLD in the original studies, and the performances of
these scores have not been validated, evaluated, and
compared directly in a large general population. In ad-
dition, whether these non-invasive scores of NAFLD
can predict clinical outcome remains largely unknown.
In this study, we aimed to validate and evaluate the
performance of these non-invasive prediction scores
of NAFLD in predicting ultrasonography-diagnosed
NAFLD in a representative general adult population
in the USA (cross-sectional NAFLD prediction co-
hort), and to test if the marker can predict mortality
in the general population (prospective mortality pre-
diction cohort).
Methods
Participant recruitment
Data from the third National Health and Nutrition Exa-
mination Survey (NHANES III) were used [10]. NHANES
III was conducted by the National Center for Health
Statistics (NCHS) from 1988 to 1994, using a stratified
multistage probability sample that represented the civi-
lian non-institutionalized population in the USA. Par-
ticipants gave written consent before participation, and
ethics approval was obtained from the Human Subjects
Committee of the US Department of Health and Human
Services.
We studied people aged 20 to 74 years who partici-
pated in the NHANES III survey. Laboratory tests were
carried out in a mobile examination center (n = 14,797)
(see Additional file 1: Figure S1). Because all non-invasive
score formulae require levels of biomarkers in fasting
blood, we included participants with blood taken after
fasting for at least 8 hours fasting (n = 9,268). Of those,
participants with factors that can confound the diagno-
sis of NAFLD (including excessive alcohol consumption,
defined as >21 drinks/week in men and >14 drinks/week
in women [4]; viral hepatitis, defined as positive serum
hepatitis B surface antigen and positive serum hepatitis
C antibody; iron overload, defined as transferrin satu-
ration ≥50%; or pregnancy) were excluded (n = 1,089).
The LFS formula includes fasting insulin level, there-
fore we further excluded participants who were using
insulin or other medications for diabetes (n = 315). This
left 7,864 participants, and once the appropriate exclu-
sion criteria were adopted for each aim (see Additional
file 1: Figure S1), we had 5,184 and 5,892 participantsincluded in the analysis of Aim 1 (evaluation of the per-
formance of non-invasive prediction scores of NAFLD
in predicting ultrasound-diagnosed NAFLD) and Aim
2 (evaluation of the relationship between non-invasive
prediction scores of NAFLD and mortality), respectively.
Definition of NAFLD
In the original NHANES III between 1988 and 1994, gall
bladder ultrasonography video images were recorded
using a Toshiba Sonolayer SSA-90A and Toshiba video
recorder. Between 2009 and 2010, hepatic steatosis (fatty
liver) was assessed by archived video images being re-
reviewed by three ultrasonography readers (trained by a
board-certified radiologist specializing in hepatic im-
aging), who graded the presence of fat within the hepatic
parenchyma.
The following information was recorded on a standard
paper collection form: 1) presence of liver-to-kidney
contrast; 2) degree of the brightness of the liver par-
enchyma; 3) presence of deep beam attenuation; 4)
presence of echogenic walls in the small intrahepatic
vessels, and (5) definition of the gallbladder walls. Fi-
nally, an overall primary finding was given based on
the presence or absence of each of the five parameters.
The liver was graded as having no, mild, moderate, or
severe hepatic steatosis. Of the 13,983 participants with
hepatic imaging records, 13,856 of them could be gra-
ded [7]. Detailed descriptions and procedures have been
provided previously [7,11]. In the absence of a standard
definition, we defined NAFLD as moderate or severe
hepatic steatosis, and non-NAFLD as no or mild hep-
atic steatosis [12]. The overall intra-rater and inter-rater
κ statistics for reliability of the dichotomized out-
comes (“no or mild” and “moderate or severe”) were
0.77 (95% CI 0.73 to 0.82) and 0.70 (95% CI 0.64 to
0.76), respectively [11].
Non-invasive markers of NAFLD
The non-invasive markers of NAFLD were calcula-
ted based on the equations reported in the literature
[6-9]. In brief, FLI includes body mass index (BMI),
γ-glutamyltranspeptidase, triglycerides, and waist cir-
cumference; HSI includes aspartate aminotransferase
(AST)/alanine aminotransferase (ALT) ratio, BMI, dia-
betes, and sex; LAP includes sex, triglycerides, and waist
circumference; and LFS includes AST/ALT ratio, dia-
betes, fasting AST level, fasting insulin level, and MetS.
The SteatoTest was not included in the current study,
as this test is a commercially one, and the calculation
formula is not disclosed. The threshold used in the
current study also adopted the cutoff points sugges-
ted in the literature: the high/low cutoff points were
≥1.257/≤ −1.413, ≥30/<30, and ≥30/<30 for LFS, HSI,
and FLI, respectively [6,7,9].
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In NHANES III, cause of death was coded using the
International Classification of Diseases. 10th Revision
(ICD-10). ICD codes I00 to I78 and E10 to E14 were
used to assess cardiovascular and diabetes mortality, re-
spectively, as in our previous studies [13,14]. Malignancy
and liver mortality were defined by the Underlying
Cause of Death (UCOD)_113 20 to 23, 25 to 26, and 43,
and UCOD_113 15, 24, and 93 to 95, respectively, as in
the literature [15]. The length of follow-up was the time
from the study examination date to death or to Decem-
ber 31, 2006, whichever was earlier.
Definition of diabetes, hypertension, and MetS
Diabetes was defined according to the latest American
Diabetes Association (ADA) guideline, which includes
fasting glucose ≥126 mg/dl, random plasma glucose ≥
200 mg/dl, or A1C ≥ 6.5. Patients were considered to
have hypertension if they had systolic blood pressure
(SBP) ≥140 or diastolic blood pressure (DBP) ≥90 mmHg,
or if they were receiving anti-hypertensive drug therapy.
MetS was defined according to the joint scientific state-
ment on harmonizing MetS [16], that is, having three or
more of the following factors: 1) elevated blood pressure
(SBP ≥ 130 mmHg and/or DBP ≥85 mmHg and/or being
in receipt of anti-hypertension drug therapy); 2) elevated
triglycerides (≥150 mg/dl (1.7 mmol/l) and/or being
in receipt of drug treatment for elevated triglycerides);
3) reduced high-density liproprotein (HDL) choles-
terol (<40 mg/dl (1.0 mmol/l) in men and <50 mg/dl
(1.3 mmol/l) in women and/or being in receipt of drug
treatment for elevated HDL cholesterol); 4) elevated
fasting glucose (≥100 mg/dl (5.6 mmol/l) and/or being
in receipt of treatment for elevated glucose); and 5)
large waist circumference (>102 cm in men and >88 cm
in women of European descent). Liver fat percentage
was estimated using the equation reported in the same
literature as the LFS [7]. The equation includes the same
variables as the LFS, but with a different calculation.
Statistical analysis
To assess model discrimination, we calculated the area
under curve (AUC) for the receiver operating character-
istic (ROC) for each non-invasive score of NAFLD. The
difference between two AUCs was compared using the
maximum likelihood estimation method [17] and imple-
mented using ROCKIT [18]. Sensitivity, specificity, posi-
tive likelihood ratio (+LR), negative likelihood ratio (−LR),
and corresponding 95% CIs were also calculated. The
non-invasive NAFLD measurement with the best per-
formance (in terms of AUC for ROC) was selected and
evaluated for its association with mortality.
In the Cox proportional hazard regression model, non-
invasive score was modeled as threshold and continuousvariables. Using the lower threshold as the reference, the
hazard ratio (HR) and 95% CI for the highest threshold
were calculated using the simple and fully adjusted Cox
regression models. In the simple model, we adjusted for
age and sex. In the full model, we adopted the adjustment
model of a recent study related to NAFLD fibrosis and
mortality [15], which includes age, sex, race/ethnicity,
income, education, diabetes, hypertension, use of lipid-
lowering medication, smoking, drinking, history of car-
diovascular disease (CVD), waist circumference, dietary
caffeine intake, HDL cholesterol, triglycerides, transfer-
rin saturation and C-reactive protein. P ≤ 0.05 was con-
sidered significant. The proportional hazards assumption
was evaluated by including time-dependent covariates in
the full regression model; the overall test of proportional
hazards was not significant (P > 0.05) suggesting that the
proportional assumption was valid. To gain additional
insight into the potential nonlinearity of the effect of LFS,
we examined the Cox regression models using penalized
spline. Two degrees of freedom (df) used in the spline be-
cause the model had the lowest Akaike’s information cri-
terion (AIC) (best fit) when df = 2. Sample weights that
accounted for the unequal probabilities of selection, over-
sampling, and non-response were applied in all analyses
using the complex sampling module in SPSS (V18.0; SPSS
Inc, Chicago, IL, USA) or R software (V2.15.0) [19]. All
values presented were weighted to represent the civilian
population of the USA.
We also evaluated the ability in risk reclassification
using integrated discrimination improvement (IDI) [20]
and category-less net reclassification improvement (NRI)
[20]. IDI was used to compare the difference in discrim-
ination slopes [21], while category-less NRI was used to
compare classifications from two models for changes by
outcome for a net calculation of changes in the right dir-
ection. Estimated risk of death of different models was
calculated using the equation of 1/(1 + exp(−1 × XBeta)).
Analyses were performed using R software (V2.15.0) [19].
Results
Cross-sectional NAFLD prediction cohort
Of the 5,184 participants included for the AUC study,
18.4% (16.5 to 20.4%) had NAFLD. The characteristics
of this cohort are provided in Table 1. For NAFLD predic-
tion, LFS was the best performer for predicting NAFLD,
with an AUC of 0.771 (P < 0.001), whereas the lowest
AUC (0.732) was observed for HSI (Table 2). Using max-
imum likelihood estimation, the difference between the
AUC of LFS and other markers (FLI, LAP, and HSI) was
statistically significant (all P < 0.01). Interestingly, the diag-
nostic accuracy of these markers differed by race/ethnicity
(Table 2). The sensitivity and specificity, and the + LR
and − LR of the suggested high and low cutoff points for
excluding/including NAFLD are provided in Table 3 and
Table 1 Characteristics of participants in the cross-sectional NAFLD prediction cohort according to NAFLD statusa
Characteristics No NAFLD (n = 4,117) NAFLD (n = 1,067) P value
Value 95% CI Value 95% CI
Age, years 40.42 39.59 to 41.25 45.32 43.97 to 46.67 <0.001
Female sex, % 52.6 50.4 to 54.7 45.6 41.7 to 49.5 0.005
Race/ethnicity, % <0.001
Non-Hispanic white 74.9 71.2 to 78.3 73.6 69.6 to 77.3
Non-Hispanic black 11.6 10.1 to 13.4 8.7 7.3 to 10.3
Mexican–American 4.7 3.7 to 5.8 7.6 6.2 to 9.3
Other 8.8 6.5 to 11.8 10.1 7.3 to 13.8
Education 0.001
< High school 5.5 4.2 to 7.1 8.4 6.4 to 11.1
High school 14.1 12.5 to 16.0 18.9 15.6 to 22.8
> High school 80.4 77.7 to 82.8 72.6 67.8 to 77.0
Smoking <0.001
Never 48.6 46.2 to 51.1 41.9 38.1 to 45.7
Former 23.2 21.5 to 25.1 32.8 29.4 to 36.5
Current 28.1 25.8 to 30.6 25.3 21.7 to 29.3
Diabetes, % 1.9 1.6 to 2.2 9.8 7.6 to 12.5 <0.001
Hypertension, % 16.0 14.6 to 17.6 33.7 29.9 to 37.6 <0.001
Lipid-lowering medication, % 2.4 1.8 to 3.0 5.0 3.4 to 7.1 <0.001
History of CVD, % 1.8 1.3 to 2.3 3.9 2.8 to 5.4 0.002
Metabolic syndrome, % 16.9 15.3 to 18.7 54.8 51.2 to 58.5 <0.001
Abdominal obesity, % 28.0 26.5 to 29.5 65.2 61.3 to 68.9 <0.001
Hypertriglyceridemia, % 22.8 20.5 to 25.3 54.3 50.4 to 58.2 <0.001
Impaired fasting glucose, % 20.1 18.5 to 21.8 42.1 38.4 to 46.0 <0.001
Low HDL level, % 35.50 32.7 to 38.5 60.1 54.9 to 65.0 <0.001
Body mass index, kg/m2 25.72 25.51 to 25.93 30.29 29.76 to 30.82 <0.001
Waist circumference, cm 88.82 88.35 to 89.3 101.75 100.36 to 103.13 <0.001
Serum cholesterol, mg/dl 199.83 198.5 to 201.17 208.63 205.63 to 211.63 <0.001
Serum triglycerides, mg/dl 117.71 114.18 to 121.24 192.30 183.44 to 201.15 <0.001
Serum HDL cholesterol, mg/dl 51.04b 50.15 to 51.93 42.91d 41.67 to 44.15 <0.001
Plasma glucose, mg/dl 94.07c 93.41 to 94.73 104.95 102.56 to 107.33 <0.001
Serum insulin, μU/ml 8.80 8.54 to 9.06 16.09 14.85 to 17.33 <0.001
SBP, mmHg 118.42 117.55 to 119.3 125.7e 124.7 to 126.7 <0.001
AST, U/L 19.60 19.21 to 20 25.24 24.31 to 26.17 <0.001
ALT, U/L 15.70 15.03 to 16.36 25.68 24.27 to 27.09 <0.001
GGT, U/L 24.42 23.69 to 25.15 41.61 37.77 to 45.44 <0.001
FLI 34.70 33.41 to 35.99 67.56 64.92 to 70.2 <0.001
HSI 33.10 32.7 to 33.49 39.26 38.64 to 39.89 <0.001
LFS −1.92 −2.03 to to 1.82 0.21 −0.04 to 0.46 <0.001
Liver fat percentage, % 2.45 2.33 to 2.56 5.88 5.49 to 6.27 <0.001
LAP 39.74 38.08 to 41.40 91.71 86.35 to 97.06 <0.001
ALT, alanine aminotransferase: AST, aspartate aminotransferase; CVD, cardiovascular disease; FLI, fatty liver index; GGT, gamma-glutamyl transferase; HDL,
high-density lipoprotein; HSI, hepatic steatosis index; LAP, lipid accumulation product; LFS, liver fat score; NAFLD, non-alcoholic fatty liver disease SBP, systolic
blood pressure.
aNo NAFLD: no or mild hepatic steatosis; NAFLD: moderate or severe hepatic steatosis.
Numbers of participants: b4108; c4109; d1061; e1049.
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Table 2 Quality of prediction scores in predicting NAFLD
NAFLD prediction
scores
All participants
(n = 5,184; 1067 cases)
Non-Hispanic white
(n = 1,953; 376 cases)
Non-Hispanic black
(n = 1,577; 244 cases)
Mexican-American
(n = 1,409; 401 cases)
Others
(n = 245; 46 cases)
AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
LFS 0.771 0.754 to 0.787 0.78 0.753 to 0.808 0.711 0.674 to 0.748 0.781 0.754 to 0.808 0.865 0.804 to 0.926
FLI 0.757 0.74 to 0.774 0.778 0.75 to 0.807 0.706 0.668 to 0.745 0.764 0.737 to 0.791 0.788 0.708 to 0.867
LAP 0.741 0.723 to 0.758 0.767 0.739 to 0.795 0.694 0.654 to 0.733 0.726 0.698 to 0.755 0.761 0.683 to 0.84
HSI 0.732 0.714 to 0.749 0.735 0.705 to 0.764 0.673 0.635 to 0.711 0.760 0.733 to 0.787 0.779 0.705 to 0.854
AUC, area under the curve; FLI, fatty liver index; HSI, hepatic steatosis index; LAP, lipid accumulation product; LFS, liver fat score; NAFLD, non-alcoholic fatty
liver disease.
All P < 0.001.
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used to calculate the diagnostic accuracy and the charac-
teristics of true and false positive, and true and false
negative (based on the LFS threshold) are provided in
Additional file 1: Tables S2 and S3.
Prospective mortality prediction cohort
Of the several NAFLD non-invasive prediction scores
tested, the LFS gave the best performance. As our sec-
ond aim was to investigate the relationship of the best
non-invasive score with outcome, we tested if LFS was
associated with mortality. Table 4 shows the characteris-
tics of the participants. During a median follow-up of
14.7 years (range 0.1 to 18.2 years) and 83,830.5 person-
years, 793, 311, 209, 58, and 17 participants died from
all, cardiovascular-, malignancy-, diabetes-, and liver-
related causes, respectively. Higher LFS were associated
with all causes of mortality tested, except malignancy-
related causes.
The results of Cox regression analysis are shown in
Table 5. Participants in the high LFS group had a 60%
higher risk (HR = 1.6; 95% CI 1.01 to 2.54; P = 0.048 in
full model) of all-cause mortality than the intermediate
LFS group. For cardiovascular mortality, participants
in the high LFS group was associated with 2.24-fold
(95% CI 1.03 to 4.88; P = 0.042 in full model) and 2.3-fold
(95% CI 1.19 to 4.48; P = 0.015 in full model) increase inTable 3 Sensitivity and specificity of exclusion/inclusion cutof
prediction cohort and literature
NAFLD definition Non-invasive
NAFLD score
Cutoff point SP, % 95% CI,
No to mild versus
intermediate to
severe steatosis)
LFS Inclusion ≥1.257 96.43 95.82 to
Exclusion ≤ − 1.413 67.94 66.49 to
FLI Inclusion ≥60 73.60 72.22 to
Exclusion <30 48.77 47.24 to
HSI Inclusion ≥36 69.35 67.91 to
Exclusion <30 29.75 28.36 to
AUC, area under the curve; FLI, fatty liver index; HSI, hepatic steatosis index; LAP, lip
disease; SN, sensitivity; SP, specificity.risk of death compared with the low and intermediate LFS
groups. For liver mortality, participants in the high LFS
group had a 31.25-fold (95% CI 3.13 to 333.33; P = 0.004
in full model) and 30.3-fold (95% CI 4 to 250; P = 0.001 in
full model) increase in risk of death compared with the
low and intermediate LFS groups. The Kaplan–Meier sur-
vival curves for cardiovascular and liver-related mortality
are provided in Figure 1. When LFS was treated as con-
tinuous variable, a one-unit increase of LFS was associated
with increased mortality of all-cause and cardiovascular-,
liver-, and diabetes-related mortality, with HRs of 1.09
(95% CI 1.01 to 1.19; P = 0.039), 1.11 (95% CI 1.03 to 1.19;
P = 0.006), 1.32 (95% CI 1.12 to 1.55; P = 0.001), and 1.21
(95% CI 1.02 to 1.44; P = 0.034), respectively (Table 5),
after full adjustment. Similar results were obtained after
further adjustment of the NAFLD fibrosis score (NFS).
The relationship between LFS and cardiovascular mortal-
ity as examined by penalized regression spline is shown in
Figure 2.
Age, sex, hypertension, and diabetes are commonly
used in assessing risk of mortality. We therefore evaluated
whether addition of LFS (categorical: low/intermediate/
high risk of NAFLD) in a basic clinical model composed
of these traditional risk factors could improve the risk pre-
diction. Risk reclassification with IDI showed a modest
positive shift to improvement when LFS was added in the
basic clinical model (IDI: 0.0131; 95% CI 0.009 to 0.017;f points of LFS, FLI, and HSI in the cross-sectional NAFLD
% SN, % 95% CI, % Reported SP, % Reported SN, % Ref
96.98 26.34 23.71 to 29.09 95 51 [7]
69.36 73.95 71.20 to 76.56 52 95
74.94 67.48 64.58 to 70.29 86 61 [6]
50.31 84.44 82.13 to 86.57 64 87
70.75 66.26 63.33 to 69.10 92 46 [9]
31.18 91.38 89.53 to 92.99 40 92.50
id accumulation product; LFS, liver fat score; NAFLD, non-alcoholic fatty liver
Table 4 Characteristics of participants in the prospective mortality prediction cohort according to different LFS
thresholds
Characteristics Low LFS (n = 3,524) Intermediate LFS (n = 1,890) High LFS (n = 478) P value
Value 95% CI Value 95% CI Value 95% CI
Age, years 39.23 38.34 to 40.13 45.50 44.28 to 46.71 45.04 42.78 to 47.29 <0.001
Sex, female % 56.40 54.1 to 58.7 42.30 39.3 to 45.3 45.70 38.1 to 53.5 <0.001
Race/ethnicity, % <0.001
Non-Hispanic white 78.40 75.5 to 81.1 74.10 69.3 to 78.4 73.30 68.0 to 78.0 <0.001
Non-Hispanic black 10.30 8.9 to 11.8 10.50 8.8 to 12.5 10.90 8.6 to 13.7 <0.001
Mexican–American 4.20 3.5 to 5.1 6.40 5.1 to 8.0 7.80 5.3 to 11.2 <0.001
Other 7.10 5.4 to 9.3 9.00 5.9 to 13.4 8.00 5.6 to 11.5 <0.001
Education, % <0.001
< High school 4.10 3.2 to 5.2 8.20 6.0 to 11.0 8.10 5.5 to 11.7 <0.001
High school 13.30 11.7 to 15.0 18.80 15.6 to 22.4 16.80 13.8 to 20.3 <0.001
> High school 82.60 80.3 to 84.7 73.10 68.4 to 77.3 75.10 70.1 to 79.6 <0.001
Smoking, % <0.001
Never 49.20 46.2 to 52.3 41.00 37.3 to 44.8 47.90 40.3 to 55.5 <0.001
Former 21.60 19.6 to 23.7 33.20 29.5 to 37.1 32.30 25.9 to 39.5 <0.001
Current 29.20 26.4 to 32.2 25.80 23.1 to 28.6 19.80 14.1 to 27.1 <0.001
Diabetes, % 0.20 0.1 to 0.3 5.70 4.6 to 7.0 26.20 21.3 to 31.7 <0.001
Hypertension, % 10.00 8.7 to 11.4 32.70 29.6 to 36.0 45.40 39.6 to 51.3 <0.001
Lipid-lowering medication, % 1.10 .7 to 1.8 5.40 4.1 to 7.1 7.20 4.4 to 11.6 <0.001
History of CVD, % 1.30 .9 to 1.9 3.40 2.4 to 4.8 5.10 3.1 to 8.2 <0.001
Poverty income ratio 3.25 3.09 to 3.4 2.98 2.76 to 3.2 2.83 2.54 to 3.11 0.003
Waist circumference, cm 85.22 84.74 to 85.71 100.22 99.52 to 100.92 112.22 110.51 to 113.93 <0.001
Dietary caffeine intake, mg 272.81 251.75 to 293.87 276.43 234.41 to 318.45 216.06 189.12 to 243 0.222
Serum cholesterol, mg/dl 196.06 194.01 to 198.11 213.02 209.91 to 216.14 218.33 211.56 to 225.1 <0.001
Serum HDL cholesterol, mg/dl 53.38 52.51 to 54.25 43.81 42.74 to 44.89 39.06 37.89 to 40.23 <0.001
Serum transferrin saturation, % 27.78 27.25 to 28.31 26.25 25.55 to 26.95 25.54 23.88 to 27.2 <0.001
Serum C-reactive protein, mg/dl 0.33 0.31 to 0.35 0.45 0.42 to 0.49 0.58 0.5 to 0.66 <0.001
Drinks/weeka 2.68 2.45 to 2.9 2.32 2.01 to 2.64 1.62 1.11 to 2.13 <0.001
LFS −2.53 −2.58 to −2.48 −0.41 −0.46 to −0.36 3.20 2.83 to 3.57 <0.001
Mortality
All causes 8.90 7.7 to 10.2 13.60 11.4 to 16.2 17.70 12.9 to 23.9 <0.001
CVD-related 2.80 2.3 to 3.5 5.10 4.0 to 6.4 9.00 5.4 to 14.8 <0.001
Liver-related 0.10 0.0 to 0.3 0.10 0.0 to 0.2 1.20 0.3 to 5.2 0.069
Diabetes-related 0.20 0.1 to 0.5 0.90 0.6 to 1.5 3.90 2.0 to 7.4 <0.001
Malignancy-related 2.80 2.1 to 3.8 3.60 2.5 to 5.2 2.00 1.0 to 4.2 0.698
CVD, cardiovascular disease; LFS, liver fat score; NAFLD, non-alcoholic fatty liver disease.
aA drink was defined as a 12-oz beer, a 4-oz glass of wine, or 1-oz of liquor (spirits).
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less NRI (NRI: 0.133; 95% CI 0.054 to 0.211; P < 0.001).
Discussion
Using a large, nationally representative cohort with more
than 10 years of follow-up and ultrasonographic data,
we have demonstrated that LFS is the best predictionscore for ultrasonography-diagnosed NAFLD, and can
predict mortality, including cardiovascular- and liver-
related mortality.
It is important to find an easy and cost-effective way
to screen for NAFLD. Of the several non-invasive scores
we tested, LFS showed the best performance in iden-
tifying ultrasonography-diagnosed NAFLD. Notably, LFS
Table 5 Association between LFS and mortality
Mortality from: Simple modela Full modelb Full model + NFS adjustmentb
HR 95% CI P value HR 95% CI P value HR 95% CI P value
All causes
Low (ref) versus high LFS 1.51 0.99 to 2.3 0.056 1.59 0.93 to 2.72 0.087 1.65 0.96 to 2.85 0.07
Int (ref) versus high LFS 1.52 1.03 to 2.23 0.034 1.60 1.01 to 2.54 0.048 1.61 1 to 2.58 0.049
LFS (continuous) 1.07 0.99 to 1.14 0.082 1.09 1.01 to 1.19 0.039 1.1 1.024 to 1.19 0.011
CVD
Low (ref) versus high LFS 2.29 1.24 to 4.26 0.009 2.24 1.03 to 4.88 0.042 2.30 1.02 to 5.19 0.046
Int (ref) versus high LFS 2.20 1.18 to 4.12 0.015 2.30 1.19 to 4.48 0.015 2.32 1.18 to 4.55 0.015
LFS (continuous) 1.11 1.04 to 1.19 0.002 1.11 1.03 to 1.19 0.006 1.13 1.05 to 1.21 <0.001
Liver disease
Low (ref) versus high LFS 9.80 2.01 to 47.62 0.006 31.25 3.13 to 333.33 0.004 46.45 5.13 to 420.51 <0.001
Int (ref) versus high LFS 17.24 2.6 to 111.11 0.004 30.30 4–250 0.001 32.99 4.57 to 237.95 <0.001
LFS (continuous) 1.25 1.14 to 1.36 <0.001 1.32 1.12 to 1.55 0.001 1.3 1.12 to 1.51 <0.001
Diabetes
Low (ref) versus high LFS 15.87 6.02 to 41.67 <0.001 2.87 0.65 to 12.66 0.161 3.13 0.67 to 14.56 0.143
Int (ref) versus high LFS 5.24 2.24 to 12.2 <0.001 1.98 0.71 to 5.52 0.185 2.04 0.72 to 5.79 0.176
LFS (continuous) 1.37 1.27 to 1.48 <0.001 1.21 1.02 to 1.44 0.034 1.21 1.03 to 1.42 0.024
Malignancy
Low (ref) versus high LFS 0.55 0.25 to 1.24 0.147 0.75 0.27 to 2.11 0.578 0.75 0.27 to 2.09 0.576
Int (ref) versus high LFS 0.65 0.29 to 1.44 0.281 0.76 0.32 to 1.79 0.519 0.76 0.32 to 1.79 0.518
LFS (continuous) 0.92 0.86 to 0.99 0.026 0.97 0.87 to 1.07 0.521 0.95 0.8 to 1.12 0.495
CVD, cardiovascular disease; Int, intermediate; LFS, liver fat score.
aSimple model: adjusted for age and sex.
bFull model: further adjusted for race/ethnicity, education, income, diabetes, hypertension, history of CVD, lipid-lowering medication, smoking status, waist
circumference, alcohol consumption, caffeine consumption, total cholesterol, high-density lipoprotein cholesterol, transferrin saturation, and C-reactive protein;
Because of smaller numbers of liver- and diabetes-related deaths, we did not adjust for education, income, history of CVD, lipid-lowering medication, and
C-reactive protein in the full model.
Cheung et al. BMC Medicine 2014, 12:154 Page 7 of 11
http://www.biomedcentral.com/1741-7015/12/154was derived using 1H-MRS-diagnosed NAFLD, whereas
FLI, HSI, and LAP were derived from ultrasonography-
diagnosed NAFLD. For those scores derived from ul-
trasonography, the definitions of the NAFLD were also
somewhat different (see Additional file 1: Table S4). Ul-
trasonography is a semi-quantitative imaging technique,
and the definitions of NAFLD differed between studies.
By contrast, 1H-MRS is by far the most sensitive and
quantitative imaging tool in identifying hepatic steatosis.
This could be the reason why the non-invasive score
(LFS) derived from 1H-MRS performed better and more
robustly in identifying cases in the current study. As there
is no standard definition of ultrasonography-diagnosed
NAFLD for good measurement, we used three additio-
nal definitions to test the performance of different non-
invasive indices (see Additional file 1: Table S5), and the
LFS still came out best. We evaluated whether combining
all prediction scores (combined score) could improve the
NAFLD prediction. The AUC of the combined score in-
creased to 0.782 (95% CI 0.766 to 0.798), suggesting that
there are unique NAFLD predicting components being
captured in different prediction scores.Interestingly, there was a difference in the diagnostic
accuracy of the different non-invasive scores, with the
lowest diagnostic accuracy being observed in black pa-
tients for all tested scores, suggesting that the clinical
risk factors of NAFLD could be ethnicity-specific and
particularly different in black populations. Like other dis-
ease predictions [22], deriving an ethnicity- or population-
specific prediction model may be required to achieve a
high accuracy of NAFLD prediction. Notably, although
there was an observed difference in the diagnostic ac-
curacy of LFS for NAFLD, no significant interaction
(P > 0.05) between LFS and race/ethnicity on mortality
was observed, therefore, no subgroup analysis was per-
formed in the subsequent analyses.
LFS was calculated based on the AST/ALT ratio, dia-
betes, fasting AST level, fasting insulin level, and MetS.
Given that diabetes and MetS are known to be asso-
ciated with mortality, the association between LFS and
mortality could be attributable to these factors. However,
the components of MetS were adjusted for in the full
model, suggesting that the association of LFS with mor-
tality may be independent of these factors. A number of
Figure 1 Kaplan–Meier curves of mortality curves according to
different liver fat score (LFS) thresholds. (a) Cardiovascular-related
and (b) liver-related mortality.
Figure 2 Association between liver fat score (LFS) and cardiovascular
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circumference thresholds for abdominal obesity in defin-
ing MetS. In addition to the threshold suggested by
ATPIII [16], we also used the population-specific thresh-
old suggested by the International Diabetes Federation,
and the findings remained unchanged (data not shown).
In the literature on FLI, LFS, and HSI, various high
and low cutoff points have been proposed to include and
exclude NAFLD [6,7,9]. The high cutoff point should
have a high specificity and + LR, while the low cutoff
point should have a high sensitivity and low − LR. In
general, the diagnostic performance of the defined cutoff
points of the NAFLD prediction scores was not the same
as that originally reported in the literature because the
sample populations were different (Table 3). The high cut-
off point of LFS had a slightly higher specificity (96.4%) in
the current study than the figure (95%) reported in the lit-
erature, meaning that study participants with a high LFS
were very likely to have a higher risk of mortality.
Two previous studies validated the non-invasive predic-
tion scores in adults [23,24]. Koehler et al. validated FLI
and LAP in 2,652 participants in the Rotterdam Study.
FLI and LAP had an AUC of 0.813 and 0.786, respectively,
in predicting ultrasonography-diagnosed NAFLD. FLI had
a higher AUC in the Rotterdam Study than in the current
study. Interestingly, the Rotterdam Study used the scoring
protocol of Hamaguchi et al. [25], and the one used by
NHANES was an algorithm derived based on that same
publication. The Rotterdam Study was a population-
based cohort study of elderly inhabitants of a district
of Rotterdam, whereas NHANES was a nationally rep-
resentative population-based study with participants
of different races/ethnicities and age. LFS was previ-
ously validated in a study of 40 non-diabetic patients
with biopsy-proven NAFLD and 85 healthy controls [23],
which showed that LFS had an AUC of 0.86. Although the
AUC from different validation studies cannot be com-
pared directly, our study is in agreement with previousmortality via penalized regression splines.
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followed by FLI and LAP. Although no validation study
has been performed for HSI, our study suggested that HSI
is better than LAP as a predictor of NAFLD.
Although identifying people with NAFLD is important,
identifying people with adverse clinical outcome is even
more important, as NAFLD consists of a wide spec-
trum of conditions, ranging from simple steatosis to
cirrhosis with varying prognosis. In concordance with
previous NHANES reports [12,15], our study did not re-
veal any significant association between ultrasonography-
diagnosed NAFLD and mortality (data not shown). This
finding is intriguing. Ultrasonography-diagnosed NAFLD
is not associated with mortality, whereas LFS, a marker of
NAFLD, is associated with mortality. This could be due to
the reason mentioned earlier, namely, that LFS was de-
rived using the sensitive and quantitative imaging tool
1H-MRS, whereas other NAFLD prediction scores were
derived using a less sensitive semi-quantitative ultrasonog-
raphy. In fact, we found no association of other markers
of NAFLD with mortality (se Additional file 1: Table S5),
further suggesting that 1H-MRS-derived LFS may be more
superior in identifying NAFLD and predicting clinical
outcome.
We then investigated which individual component of
the LFS was associated with CVD mortality in the multi-
variable model, and found the only significant associ-
ation observed Qa with fasting serum insulin (estimate
of 1.02; 95% CI 1.01 to 1.03; P < 0.001), suggesting that
fasting serum insulin may be the main driver for the ob-
served association.
Notably, high LFS is also associated with low transfer-
rin saturation (Table 4). In our previous study, we showed
that low transferrin saturation was robustly associated
with pre-diabetes [26]. These observations suggested
that elevated insulin resistance might be the key fac-
tor leading to mortality in people with NAFLD, which
may also explain why LFS can predict mortality whereas
ultrasonography-diagnosed NAFLD cannot. Another pos-
sibility is that high LFS indicates the presence of other
NAFLD-related conditions, such as NASH and fibrosis. In
participants with NAFLD, high LFS is associated with high
NFS (data not shown), which is a prediction score of
NAFLD fibrosis [27], although NFS does not predict
NAFLD (data not shown) nor is it significantly associated
with mortality in the general population (see Additional
file 1: Table S5). However, further adjustment of NFS re-
vealed that the effect of LFS is independent of NFS
(Table 5), suggesting that the association between LFS and
mortality may be independent of NAFLD fibrosis. Future
study is required to confirm our observations and to
examine the underlying mechanisms.
Age, sex, and presence of diabetes or hypertension are
simple risk factors that are commonly used by clinicians toevaluate mortality risk. We showed that LFS has an inde-
pendent role in predicting mortality and improved risk re-
classification. Similarly, although the Framingham Risk
Score (FRS) was not intended for use in mortality predic-
tion, we found that the associations of LFS with cardiomet-
abolic disease related mortality were independent of FRS
(see Additional file 1: Table S6). These findings suggest that
abnormal liver function may play a role in mortality deter-
mination, independently of traditional risk factors.
Our study has several strengths. The study population
is large, multiethnic, nationally representative, and well-
characterized, with data on ultrasonography-diagnosed
NAFLD, multiple risk factors, and potential confounders.
The long follow-up and the large number of events pro-
vided ample statistical power. The wide range of col-
lected data from NHANES III allowed construction of
four different non-invasive prediction scores simultan-
eously, so that they could be compared in parallel and
with different definitions of NAFLD.
Nevertheless, there are limitations. The major limita-
tion of the current study is the use of ultrasonography-
diagnosed NAFLD, which can lead to misclassification
error. In the absence of a standard definition, we defined
NAFLD as presence of moderate or severe hepatic stea-
tosis, while non-NAFLD was defined as presence of no
or mild hepatic steatosis, as in previous study. The case
definition, especially when mild hepatic steatosis was de-
fined as non-NAFLD, could be a potential source of bias.
This classification could have led to underestimation of
the NAFLD prevalence in the current study, which was
reported to be 20% to 33% in the general population
[28], although the lower prevalence observed could also
be due to the lower prevalence of obesity in the current
study [29]. It is acknowledged that ultrasonography has
limited sensitivity and specificity in diagnosing NAFLD,
especially when less than 33% of the liver parenchyma is
infiltrated by fat [30,31] and in the presence of liver cir-
rhosis that may lead to decreased hepatic steatosis. To
confirm our findings, we defined NAFLD in different
ways and still found that LFS was the best marker of
NAFLD (Table 4; see Additional file 1: Table S7), and
participants with mild hepatic steatosis also did not have
increased mortality compared with those without hepatic
steatosis (see Additional file 1: Table S8).
Although liver biopsy is considered the gold standard
in diagnosing NAFLD, it is not justifiable to perform
liver biopsy in large numbers of asymptomatic individ-
uals, therefore ultrasonography is still considered an ac-
ceptable first-line screening procedure for NAFLD in
clinical practice [32]. However, ultrasonography cannot
distinguish between NASH, fibrosis or cirrhosis.
The prediction score named the SteatoTest, was not
included in the current study; whether it is superior to
LFS or otherwise requires further study.
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cases of liver-related mortality, which led to unreliable
estimates, and could also be a potential source of bias,
therefore cautious interpretation is required.
Conclusion
In conclusion, we found that 1H-MRS derived NAFLD
prediction score LFS was the most robust non-invasive
score identifying NAFLD in this US population and pre-
dicted mortality. NAFLD is highly prevalent, and can be
associated with morbidity and mortality if left unidenti-
fied. Our findings suggest that LFS may be a promising
tool for large-scale NAFLD screening. If confirmed in
future studies, LFS may be a useful marker for large-
scale NAFLD screening and prediction of long-term
clinical outcomes.
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